NCT06865482

Clinical Course Of Disease In Participants With FA-CM

Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 65 (estimated)
• Sponsor: Lexeo Therapeutics · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)

Detailed description

Study LX2006-02 is a prospective, longitudinal, low-intervention, multicenter, global study aimed at characterizing the nature and rate of cardiac disease progression in participants with genetically confirmed FA-CM. After completing at least 26 weeks in Study LX2006-02, participants who meet the eligibility criteria may have the opportunity to participate in an LX2006 interventional study and receive gene therapy.

Conditions

• Friedreich Ataxia
• Cardiomyopathy

Timeline

• Start date: 2025-09-30
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2025-03-07
• Last updated: 2026-04-15

Locations

14 sites across 7 countries: United States, Brazil, Canada, Czechia, France, Germany, Spain